US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

1.33

-0.0201-1.49%

Volume:79.12K

Turnover:107.38K

Market Cap:3.44M

PE:-0.04

High:1.42

Open:1.34

Low:1.32

Close:1.35

52wk High:28.16

52wk Low:1.25

Shares:2.58M

Float Shares:2.56M

Volume Ratio:2.77

T/O Rate:3.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-33.3374

EPS(LYR):-95.1334

ROE:-672.22%

ROA:-134.79%

PB:1.10

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Calidi Biotherapeutics publishes RedTail virotherapy platform presentation

Calidi Biotherapeutics announces annual shareholder meeting via webcast

Calidi Biotherapeutics to present RedTail platform data at oncolytic virus conference

Calidi Biotherapeutics to present RedTail systemic virotherapy data at ASGCT meeting

Calidi Biotherapeutics director Allan Camaisa to leave board at annual meeting

Calidi Biotherapeutics to present new CLD-401 preclinical data at AACR meeting

Calidi Biotherapeutics to present AACR data on RedTail TROP-2 T-cell engager candidate

Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000

Calidi Biotherapeutics Inc: Q4 Net Loss per Share $0.57

THOMSON REUTERS

Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval

Calidi Biotherapeutics Announces Partnership With Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of Cld-401 Clinical Trials

THOMSON REUTERS

Calidi Biotherapeutics partners with Avance Clinical on CLD-401 trial launch in Australia

Calidi Biotherapeutics presents CLD-401 manufacturing process at BioProcessing Summit in Barcelona

Calidi Biotherapeutics announces proposed underwritten public offering of stock and warrants

Press Release: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering

Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why

Benzinga_recent_news

Calidi announces offering of units, no amount given

Calidi Biotherapeutics Announces Proposed Public Offering

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CLDI/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLDI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":1.3299,"timestamp":1787848802117,"preClose":1.35,"halted":0,"volume":79117,"delay":0,"changeRate":-0.014888888888888892,"floatShares":2555400,"shares":2584200,"eps":-33.337368,"marketStatus":"Trading","change":-0.0201,"latestTime":"08-27 12:42:14 EDT","open":1.34,"high":1.42,"low":1.32,"amount":107379.7127356,"amplitude":0.074074,"askPrice":1.36,"askSize":100,"bidPrice":1.28,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-33.337368,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787860800000},"marketStatusCode":2,"adr":0,"exchange":"AMEX","adjPreClose":1.35,"preHourTrading":{"tag":"盘前","latestPrice":1.32,"preClose":1.35,"latestTime":"09:00 EDT","volume":18827,"amount":24740.822395299998,"timestamp":1787835602111,"change":-0.03,"changeRate":-0.022222,"amplitude":0.051852},"postHourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.35,"latestTime":"18:10 EDT","volume":2012,"amount":2646.7942,"timestamp":1787782244970,"change":-0.03,"changeRate":-0.022222,"amplitude":0.02963},"volumeRatio":2.769902},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","floatShares":2555400,"roa":"-134.79%","roe":"-672.22%","lyrEps":-95.133424,"volumeRatio":2.769902,"shares":2584200,"dividePrice":0,"high":1.42,"amplitude":0.074074,"preClose":1.35,"low":1.32,"week52Low":1.25,"pbRate":"1.10","week52High":28.16,"institutionHeld":0,"latestPrice":1.3299,"eps":-33.337368,"divideRate":0,"volume":79117,"delay":0,"ttmEps":-33.337368,"open":1.34,"prevYearClose":18.72,"prevWeekClose":1.34,"prevMonthClose":1.64,"prevQuarterClose":2.72,"fiveDayClose":1.34,"twentyDayClose":1.4928,"sixtyDayClose":2.8816},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-31","symbol":"CLDI","defaultRemindTime":1785504600000,"type":"split","dateTimestamp":1785470400000,"forFactor":16,"toFactor":1,"ratio":16},{"market":"US","date":"2025-08-05","symbol":"CLDI","defaultRemindTime":1754400600000,"type":"split","dateTimestamp":1754366400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-07-15","symbol":"CLDI","defaultRemindTime":1721050200000,"type":"split","dateTimestamp":1721016000000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLDI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLDI","date":"2026-08-25","current":-0.040495,"percent":0.834286,"low":-6.02184,"twenty":-0.987057,"median":-0.480755,"eighty":-0.291524,"high":-0.088409,"avg":-0.722431,"sd":0.723164,"marketCap":3579111},"quantilePoints":[{"date":"2023-09-29","current":-3.638343,"twenty":-5.308141,"median":-4.713391,"eighty":-4.212002,"marketCap":116696199},{"date":"2023-10-06","current":-3.412521,"twenty":-4.832341,"median":-4.127586,"eighty":-3.638343,"marketCap":109453210},{"date":"2023-10-13","current":-3.406945,"twenty":-4.642021,"median":-3.525432,"eighty":-3.367913,"marketCap":109274365},{"date":"2023-10-20","current":-3.122569,"twenty":-4.220957,"median":-3.406945,"eighty":-3.283158,"marketCap":100153264},{"date":"2023-10-27","current":-2.788008,"twenty":-3.847474,"median":-3.379065,"eighty":-3.220707,"marketCap":89422557},{"date":"2023-11-03","current":-1.828933,"twenty":-3.642821,"median":-3.289849,"eighty":-2.58281,"marketCap":58661197},{"date":"2023-11-10","current":-2.263862,"twenty":-3.457685,"median":-3.122569,"eighty":-2.272784,"marketCap":72611116},{"date":"2023-11-17","current":-2.442295,"twenty":-3.40806,"median":-2.704368,"eighty":-2.257171,"marketCap":78334160},{"date":"2023-11-24","current":-2.219166,"twenty":-3.390217,"median":-2.436719,"eighty":-2.230406,"marketCap":63785485},{"date":"2023-12-01","current":-2.589027,"twenty":-3.358991,"median":-2.397687,"eighty":-2.219166,"marketCap":74416400},{"date":"2023-12-08","current":-2.860258,"twenty":-3.332227,"median":-2.436719,"eighty":-2.22591,"marketCap":82212403},{"date":"2023-12-15","current":-2.835601,"twenty":-3.283158,"median":-2.620727,"eighty":-2.230406,"marketCap":81503676},{"date":"2023-12-22","current":-2.220879,"twenty":-3.249702,"median":-2.454969,"eighty":-2.220879,"marketCap":63834719},{"date":"2023-12-29","current":-1.739688,"twenty":-3.220707,"median":-2.431143,"eighty":-2.219509,"marketCap":50003863},{"date":"2024-01-05","current":-1.752027,"twenty":-3.147103,"median":-2.407056,"eighty":-2.219166,"marketCap":50358500},{"date":"2024-01-12","current":-1.628644,"twenty":-3.080391,"median":-2.314664,"eighty":-2.158893,"marketCap":46812127},{"date":"2024-01-19","current":-1.492924,"twenty":-2.974346,"median":-2.305467,"eighty":-1.939518,"marketCap":42911116},{"date":"2024-01-26","current":-1.204827,"twenty":-2.880427,"median":-2.269438,"eighty":-1.766833,"marketCap":34630335},{"date":"2024-02-02","current":-0.987855,"twenty":-2.845464,"median":-2.230406,"eighty":-1.702674,"marketCap":28393922},{"date":"2024-02-09","current":-0.730889,"twenty":-2.828204,"median":-2.220879,"eighty":-1.569421,"marketCap":21007953},{"date":"2024-02-16","current":-0.617286,"twenty":-2.802114,"median":-2.220879,"eighty":-1.222224,"marketCap":17742652},{"date":"2024-02-23","current":-1.223953,"twenty":-2.75773,"median":-2.219166,"eighty":-1.201248,"marketCap":35180069},{"date":"2024-03-01","current":-0.737187,"twenty":-2.712314,"median":-2.219166,"eighty":-1.144986,"marketCap":21188964},{"date":"2024-03-08","current":-0.857685,"twenty":-2.707382,"median":-2.174646,"eighty":-1.007118,"marketCap":24652427},{"date":"2024-03-15","current":-0.752972,"twenty":-2.675328,"median":-2.00496,"eighty":-0.959654,"marketCap":21642662},{"date":"2024-03-22","current":-0.731293,"twenty":-2.63341,"median":-1.828933,"eighty":-0.834401,"marketCap":21365466},{"date":"2024-03-28","current":-0.690544,"twenty":-2.624956,"median":-1.776703,"eighty":-0.788933,"marketCap":20174941},{"date":"2024-04-05","current":-0.515506,"twenty":-2.614387,"median":-1.733519,"eighty":-0.77599,"marketCap":15061018},{"date":"2024-04-12","current":-0.778003,"twenty":-2.56475,"median":-1.702674,"eighty":-0.753894,"marketCap":22730126},{"date":"2024-04-19","current":-0.277851,"twenty":-2.462573,"median":-1.585461,"eighty":-0.73922,"marketCap":8117685},{"date":"2024-04-26","current":-0.277851,"twenty":-2.440065,"median":-1.494131,"eighty":-0.729834,"marketCap":8117685},{"date":"2024-05-03","current":-0.33683,"twenty":-2.428199,"median":-1.326872,"eighty":-0.713833,"marketCap":9840816},{"date":"2024-05-10","current":-0.388779,"twenty":-2.412677,"median":-1.223953,"eighty":-0.694949,"marketCap":11358553},{"date":"2024-05-17","current":-0.395215,"twenty":-2.384304,"median":-1.201804,"eighty":-0.67322,"marketCap":11848146},{"date":"2024-05-24","current":-0.389826,"twenty":-2.327552,"median":-1.110439,"eighty":-0.59822,"marketCap":11686581},{"date":"2024-05-31","current":-0.489936,"twenty":-2.314664,"median":-1.049596,"eighty":-0.481812,"marketCap":14687785},{"date":"2024-06-07","current":-0.316825,"twenty":-2.30847,"median":-0.987793,"eighty":-0.405177,"marketCap":9498101},{"date":"2024-06-14","current":-0.471065,"twenty":-2.306068,"median":-0.973968,"eighty":-0.411637,"marketCap":14122049},{"date":"2024-06-21","current":-0.417535,"twenty":-2.287195,"median":-0.942383,"eighty":-0.415168,"marketCap":12517271},{"date":"2024-06-28","current":-0.442801,"twenty":-2.275014,"median":-0.891807,"eighty":-0.416445,"marketCap":13274726},{"date":"2024-07-05","current":-0.415179,"twenty":-2.275014,"median":-0.841776,"eighty":-0.414794,"marketCap":12446661},{"date":"2024-07-12","current":-0.324606,"twenty":-2.266092,"median":-0.802632,"eighty":-0.404243,"marketCap":9731376},{"date":"2024-07-15","current":-0.338952,"twenty":-2.263862,"median":-0.798467,"eighty":-0.400509,"marketCap":10161455},{"date":"2024-08-02","current":-0.357581,"twenty":-2.257171,"median":-0.794302,"eighty":-0.396487,"marketCap":10719918},{"date":"2024-08-09","current":-0.398883,"twenty":-2.230406,"median":-0.779498,"eighty":-0.390904,"marketCap":11958114},{"date":"2024-08-16","current":-0.480755,"twenty":-2.230406,"median":-0.778003,"eighty":-0.392451,"marketCap":11175142},{"date":"2024-08-23","current":-0.500804,"twenty":-2.228501,"median":-0.759804,"eighty":-0.395268,"marketCap":11641180},{"date":"2024-08-30","current":-0.382558,"twenty":-2.220879,"median":-0.750634,"eighty":-0.391354,"marketCap":8892568},{"date":"2024-09-06","current":-0.39647,"twenty":-2.220879,"median":-0.737187,"eighty":-0.391253,"marketCap":9215934},{"date":"2024-09-13","current":-0.403425,"twenty":-2.220879,"median":-0.730361,"eighty":-0.39176,"marketCap":9377617},{"date":"2024-09-20","current":-0.384297,"twenty":-2.220879,"median":-0.726938,"eighty":-0.391253,"marketCap":8932989},{"date":"2024-09-27","current":-0.420814,"twenty":-2.219166,"median":-0.713995,"eighty":-0.389826,"marketCap":9781825},{"date":"2024-10-04","current":-0.375603,"twenty":-2.219166,"median":-0.705506,"eighty":-0.388779,"marketCap":8730885},{"date":"2024-10-11","current":-0.484689,"twenty":-2.219166,"median":-0.691943,"eighty":-0.386036,"marketCap":11266594},{"date":"2024-10-18","current":-0.559329,"twenty":-2.219166,"median":-0.675446,"eighty":-0.386036,"marketCap":13001597},{"date":"2024-10-25","current":-0.336452,"twenty":-2.219166,"median":-0.638834,"eighty":-0.386036,"marketCap":7820838},{"date":"2024-10-31","current":-0.530552,"twenty":-2.18355,"median":-0.601504,"eighty":-0.386036,"marketCap":12332679},{"date":"2024-11-08","current":-0.740861,"twenty":-2.174646,"median":-0.630927,"eighty":-0.38823,"marketCap":17221309},{"date":"2024-11-15","current":-0.849939,"twenty":-2.111632,"median":-0.664773,"eighty":-0.389367,"marketCap":22332149},{"date":"2024-11-22","current":-1.580558,"twenty":-2.067561,"median":-0.675446,"eighty":-0.389764,"marketCap":41529165},{"date":"2024-11-29","current":-1.558504,"twenty":-1.993856,"median":-0.690544,"eighty":-0.390682,"marketCap":40949688},{"date":"2024-12-06","current":-1.477638,"twenty":-1.934558,"median":-0.69736,"eighty":-0.391557,"marketCap":38824940},{"date":"2024-12-13","current":-1.374718,"twenty":-1.867215,"median":-0.712804,"eighty":-0.392499,"marketCap":36120716},{"date":"2024-12-20","current":-1.065958,"twenty":-1.812401,"median":-0.717637,"eighty":-0.394326,"marketCap":28008041},{"date":"2024-12-27","current":-1.088012,"twenty":-1.791509,"median":-0.728386,"eighty":-0.395322,"marketCap":28587518},{"date":"2025-01-03","current":-0.867469,"twenty":-1.774231,"median":-0.730361,"eighty":-0.39568,"marketCap":22792751},{"date":"2025-01-10","current":-0.992443,"twenty":-1.764344,"median":-0.73424,"eighty":-0.39647,"marketCap":26076452},{"date":"2025-01-17","current":-0.658321,"twenty":-1.752027,"median":-0.729834,"eighty":-0.39647,"marketCap":17297380},{"date":"2025-01-24","current":-0.559444,"twenty":-1.742156,"median":-0.726938,"eighty":-0.39647,"marketCap":14699393},{"date":"2025-01-31","current":-0.459906,"twenty":-1.730007,"median":-0.713995,"eighty":-0.3984,"marketCap":12084021},{"date":"2025-02-07","current":-1.088012,"twenty":-1.727397,"median":-0.721011,"eighty":-0.399734,"marketCap":28587518},{"date":"2025-02-14","current":-0.992443,"twenty":-1.707609,"median":-0.729834,"eighty":-0.399947,"marketCap":26076452},{"date":"2025-02-21","current":-0.926281,"twenty":-1.702674,"median":-0.731091,"eighty":-0.399947,"marketCap":24338022},{"date":"2025-02-28","current":-0.612521,"twenty":-1.691156,"median":-0.729834,"eighty":-0.399947,"marketCap":16094000},{"date":"2025-03-07","current":-0.624578,"twenty":-1.650578,"median":-0.723974,"eighty":-0.400284,"marketCap":16410780},{"date":"2025-03-14","current":-0.571942,"twenty":-1.617436,"median":-0.713824,"eighty":-0.401215,"marketCap":15027763},{"date":"2025-03-21","current":-0.580763,"twenty":-1.605553,"median":-0.709155,"eighty":-0.402729,"marketCap":15259553},{"date":"2025-03-28","current":-0.511219,"twenty":-1.596023,"median":-0.693342,"eighty":-0.403425,"marketCap":13432270},{"date":"2025-04-04","current":-0.459715,"twenty":-1.584987,"median":-0.688902,"eighty":-0.403425,"marketCap":10179474},{"date":"2025-04-11","current":-0.669232,"twenty":-1.579798,"median":-0.693063,"eighty":-0.404476,"marketCap":14818796},{"date":"2025-04-17","current":-0.762727,"twenty":-1.576858,"median":-0.698757,"eighty":-0.405589,"marketCap":16889069},{"date":"2025-04-25","current":-0.815708,"twenty":-1.567326,"median":-0.703771,"eighty":-0.407877,"marketCap":18062224},{"date":"2025-05-02","current":-0.791432,"twenty":-1.558504,"median":-0.712804,"eighty":-0.410381,"marketCap":17524679},{"date":"2025-05-09","current":-0.680714,"twenty":-1.556948,"median":-0.713079,"eighty":-0.410531,"marketCap":15073040},{"date":"2025-05-16","current":-0.757287,"twenty":-1.55323,"median":-0.713725,"eighty":-0.411705,"marketCap":15073040},{"date":"2025-05-23","current":-0.755462,"twenty":-1.548212,"median":-0.715532,"eighty":-0.413178,"marketCap":15036720},{"date":"2025-05-30","current":-0.635937,"twenty":-1.533867,"median":-0.715532,"eighty":-0.413252,"marketCap":12657684},{"date":"2025-06-06","current":-0.601845,"twenty":-1.49389,"median":-0.713725,"eighty":-0.413637,"marketCap":11979114},{"date":"2025-06-13","current":-0.579566,"twenty":-1.491337,"median":-0.71226,"eighty":-0.415179,"marketCap":11535691},{"date":"2025-06-20","current":-0.49788,"twenty":-1.484989,"median":-0.706232,"eighty":-0.415179,"marketCap":9909811},{"date":"2025-06-27","current":-0.38649,"twenty":-1.477638,"median":-0.701377,"eighty":-0.415179,"marketCap":7692700},{"date":"2025-07-03","current":-0.414844,"twenty":-1.438928,"median":-0.693342,"eighty":-0.413227,"marketCap":8257056},{"date":"2025-07-11","current":-1.684355,"twenty":-1.438928,"median":-0.693202,"eighty":-0.413227,"marketCap":33525394},{"date":"2025-07-18","current":-1.123887,"twenty":-1.426793,"median":-0.701377,"eighty":-0.413252,"marketCap":22369845},{"date":"2025-07-25","current":-1.408554,"twenty":-1.420297,"median":-0.706232,"eighty":-0.414526,"marketCap":28035855},{"date":"2025-08-01","current":-1.087209,"twenty":-1.418827,"median":-0.712804,"eighty":-0.414844,"marketCap":21639801},{"date":"2025-08-08","current":-0.875894,"twenty":-1.410609,"median":-0.713774,"eighty":-0.415112,"marketCap":17433803},{"date":"2025-08-15","current":-0.869891,"twenty":-1.399128,"median":-0.7168,"eighty":-0.415179,"marketCap":17269086},{"date":"2025-08-22","current":-0.293416,"twenty":-1.396772,"median":-0.714044,"eighty":-0.415112,"marketCap":5824890},{"date":"2025-08-29","current":-0.333904,"twenty":-1.384858,"median":-0.713355,"eighty":-0.413227,"marketCap":6628654},{"date":"2025-09-05","current":-0.306566,"twenty":-1.377583,"median":-0.711715,"eighty":-0.410381,"marketCap":6085957},{"date":"2025-09-12","current":-0.318282,"twenty":-1.365896,"median":-0.706232,"eighty":-0.404476,"marketCap":6318541},{"date":"2025-09-19","current":-0.308519,"twenty":-1.353336,"median":-0.701377,"eighty":-0.401215,"marketCap":6124721},{"date":"2025-09-26","current":-0.294091,"twenty":-1.33881,"median":-0.693202,"eighty":-0.399947,"marketCap":5838288},{"date":"2025-10-03","current":-0.316401,"twenty":-1.31392,"median":-0.68726,"eighty":-0.39647,"marketCap":6281193},{"date":"2025-10-10","current":-0.322486,"twenty":-1.292622,"median":-0.675448,"eighty":-0.392499,"marketCap":6401985},{"date":"2025-10-17","current":-0.326542,"twenty":-1.284205,"median":-0.672663,"eighty":-0.38922,"marketCap":6482513},{"date":"2025-10-24","current":-0.308288,"twenty":-1.276188,"median":-0.670475,"eighty":-0.387098,"marketCap":6120137},{"date":"2025-10-31","current":-0.320457,"twenty":-1.271824,"median":-0.660381,"eighty":-0.385104,"marketCap":6361721},{"date":"2025-11-07","current":-0.336683,"twenty":-1.27075,"median":-0.656627,"eighty":-0.382558,"marketCap":6683833},{"date":"2025-11-14","current":-0.308288,"twenty":-1.248314,"median":-0.646559,"eighty":-0.37908,"marketCap":6120137},{"date":"2025-11-21","current":-0.506264,"twenty":-1.227901,"median":-0.642788,"eighty":-0.378051,"marketCap":10098454},{"date":"2025-11-28","current":-0.553956,"twenty":-1.216303,"median":-0.637388,"eighty":-0.378665,"marketCap":11049758},{"date":"2025-12-05","current":-0.564962,"twenty":-1.204728,"median":-0.625828,"eighty":-0.37908,"marketCap":11269290},{"date":"2025-12-12","current":-0.539282,"twenty":-1.202359,"median":-0.624725,"eighty":-0.379407,"marketCap":10757049},{"date":"2025-12-19","current":-0.480584,"twenty":-1.198139,"median":-0.617286,"eighty":-0.380537,"marketCap":9586214},{"date":"2025-12-26","current":-0.473247,"twenty":-1.193728,"median":-0.613551,"eighty":-0.381709,"marketCap":9439860},{"date":"2026-01-02","current":-0.429224,"twenty":-1.181411,"median":-0.606978,"eighty":-0.382558,"marketCap":8561733},{"date":"2026-01-09","current":-0.425556,"twenty":-1.152719,"median":-0.601338,"eighty":-0.382558,"marketCap":8488556},{"date":"2026-01-16","current":-0.381533,"twenty":-1.123887,"median":-0.596031,"eighty":-0.382558,"marketCap":7610429},{"date":"2026-01-23","current":-0.381533,"twenty":-1.113129,"median":-0.591212,"eighty":-0.381526,"marketCap":7610429},{"date":"2026-01-30","current":-0.385201,"twenty":-1.10426,"median":-0.583111,"eighty":-0.37908,"marketCap":7683607},{"date":"2026-02-06","current":-0.308931,"twenty":-1.10252,"median":-0.580763,"eighty":-0.3778,"marketCap":6162252},{"date":"2026-02-13","current":-0.278812,"twenty":-1.090904,"median":-0.575754,"eighty":-0.374195,"marketCap":5561467},{"date":"2026-02-20","current":-0.26843,"twenty":-1.088012,"median":-0.566497,"eighty":-0.373137,"marketCap":5354376},{"date":"2026-02-27","current":-0.310362,"twenty":-1.08753,"median":-0.56401,"eighty":-0.369399,"marketCap":6190791},{"date":"2026-03-06","current":-0.282371,"twenty":-1.0848,"median":-0.559387,"eighty":-0.36189,"marketCap":5632449},{"date":"2026-03-13","current":-0.174784,"twenty":-1.08267,"median":-0.557624,"eighty":-0.357961,"marketCap":3486416},{"date":"2026-03-20","current":-0.158448,"twenty":-1.081325,"median":-0.553956,"eighty":-0.344782,"marketCap":3160553},{"date":"2026-03-27","current":-0.148693,"twenty":-1.078568,"median":-0.550287,"eighty":-0.336771,"marketCap":2965985},{"date":"2026-04-02","current":-0.134617,"twenty":-1.073376,"median":-0.545256,"eighty":-0.334923,"marketCap":2679692},{"date":"2026-04-10","current":-0.142941,"twenty":-1.067403,"median":-0.543606,"eighty":-0.331139,"marketCap":2845378},{"date":"2026-04-17","current":-0.153817,"twenty":-1.066944,"median":-0.540074,"eighty":-0.327107,"marketCap":3061874},{"date":"2026-04-24","current":-0.122077,"twenty":-1.066514,"median":-0.537448,"eighty":-0.325201,"marketCap":2430059},{"date":"2026-05-01","current":-0.13151,"twenty":-1.065958,"median":-0.535582,"eighty":-0.324514,"marketCap":2617836},{"date":"2026-05-08","current":-0.120135,"twenty":-1.065958,"median":-0.532096,"eighty":-0.32282,"marketCap":2391399},{"date":"2026-05-15","current":-0.14671,"twenty":-1.063017,"median":-0.526887,"eighty":-0.322188,"marketCap":2920400},{"date":"2026-05-22","current":-0.155096,"twenty":-1.055002,"median":-0.522094,"eighty":-0.320457,"marketCap":2951158},{"date":"2026-05-29","current":-0.15356,"twenty":-1.046879,"median":-0.517003,"eighty":-0.317116,"marketCap":2921938},{"date":"2026-06-05","current":-0.140629,"twenty":-1.031095,"median":-0.513601,"eighty":-0.31633,"marketCap":2675880},{"date":"2026-06-12","current":-0.136588,"twenty":-1.010842,"median":-0.511292,"eighty":-0.314373,"marketCap":2598987},{"date":"2026-06-18","current":-0.122848,"twenty":-1.008527,"median":-0.506543,"eighty":-0.312424,"marketCap":2337551},{"date":"2026-06-26","current":-0.153214,"twenty":-1.002903,"median":-0.500804,"eighty":-0.312345,"marketCap":2915351},{"date":"2026-07-02","current":-0.161601,"twenty":-1.000417,"median":-0.498226,"eighty":-0.310311,"marketCap":3074936},{"date":"2026-07-10","current":-0.153111,"twenty":-0.999795,"median":-0.493476,"eighty":-0.308473,"marketCap":2913405},{"date":"2026-07-17","current":-0.118234,"twenty":-0.999795,"median":-0.489941,"eighty":-0.308288,"marketCap":2249763},{"date":"2026-07-24","current":-0.107393,"twenty":-0.993913,"median":-0.489211,"eighty":-0.304549,"marketCap":2043470},{"date":"2026-07-31","current":-0.095426,"twenty":-0.992443,"median":-0.486947,"eighty":-0.304232,"marketCap":1815768},{"date":"2026-08-07","current":-0.114424,"twenty":-0.98969,"median":-0.484689,"eighty":-0.301652,"marketCap":2177268},{"date":"2026-08-14","current":-0.098443,"twenty":-0.987781,"median":-0.481792,"eighty":-0.298405,"marketCap":1873180},{"date":"2026-08-21","current":-0.198899,"twenty":-0.987327,"median":-0.481003,"eighty":-0.292874,"marketCap":3475369},{"date":"2026-08-25","current":-0.204837,"twenty":-0.987057,"median":-0.480755,"eighty":-0.291524,"marketCap":3579111}],"updateTime":1787818243603},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLDI\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628798624","title":"Calidi Biotherapeutics publishes RedTail virotherapy platform presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628798624?lang=en_us&edition=fundamental","pubTime":"2026-04-20 01:26","pubTimestamp":1776619587,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics published a research presentation outlining its RedTail dual-programmable virotherapy platform for systemic tumor targeting and localized gene delivery.RedTail uses a tumor-selective replicating extracellular enveloped vaccinia virus engineered with a chimeric CD55 to improve resistance to complement and neutralizing antibodies, supporting IV administration.Program updates highlighted CLD-401, designed for tumor-localized expression of an IL-15 superagonist, with preclinical data showing preferential tumor amplification with low off-tumor signal.Calidi also described CLD-501 as a next-generation construct intended to co-express an IL-15 superagonist with tumor-targeting bispecific T-cell engagers for localized activity in solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL6jKvGd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628782724","title":"Calidi Biotherapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628782724","media":"Reuters","labels":["shareholding","conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628782724?lang=en_us&edition=fundamental","pubTime":"2026-04-18 05:26","pubTimestamp":1776461162,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics scheduled virtual annual shareholder meeting for June 12, 2026.Shareholders set to vote on election of Class III director nominee Scott Leftwich to serve until 2029 annual meeting.Ballot includes auditor ratification for CBIZ CPAs P.C. for fiscal 2026.Investors to consider reverse stock split ratio range of 1-for-2 to 1-for-16.Meeting agenda also includes amendment to 2023 Equity Incentive Plan to raise share authorization to 1,950,000, plus potential adjournment to solicit additional votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLknnXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439445","title":"Calidi Biotherapeutics to present RedTail platform data at oncolytic virus conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439445","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627439445?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:07","pubTimestamp":1776168429,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics to present at International Oncolytic Virus Conference in Reykjavik, Iceland on April 28, 2026.Presentation to highlight RedTail platform data, including lead candidate CLD-401.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLb5QyBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","CLDI","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625952768","title":"Calidi Biotherapeutics to present RedTail systemic virotherapy data at ASGCT meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625952768","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625952768?lang=en_us&edition=fundamental","pubTime":"2026-04-08 00:29","pubTimestamp":1775579352,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics will present new preclinical data on its RedTail systemically delivered virotherapy platform at ASGCT annual meeting in Boston on May 14, 2026.Presentation is set to highlight RedTail EEV’s ability to evade immune clearance, replicate in target cells, and deliver genetic payloads to distal tumor sites.Update will include CLD-401, RedTail lead candidate engineered to express IL-15 superagonist in tumor microenvironment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL9MLNWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","CLDI","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624687167","title":"Calidi Biotherapeutics director Allan Camaisa to leave board at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2624687167","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624687167?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:01","pubTimestamp":1775163711,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics director Allan J. Camaisa plans to let his board term expire at 2026 annual stockholder meeting.Board size will shrink to five directors from six, effective at 2026 annual stockholder meeting.Scott Leftwich, Class III director, joined audit committee effective April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3vK5b6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506960","title":"Calidi Biotherapeutics to present new CLD-401 preclinical data at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506960","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506960?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:03","pubTimestamp":1775131383,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics plans to present new preclinical data on lead oncology candidate CLD-401 at AACR annual meeting in San Diego on April 17-22, 2026.Presentation will cover tumor-restricted expression of IL-15 superagonist from systemically delivered oncolytic virus, intended to activate immune response in tumor microenvironment.Company expects data to support a therapeutic effect while limiting systemic cytokine exposure, which could improve tolerability profile.CLD-401 remains in IND-enabling studies, with IND filing targeted by end of 2026 and first clinical entry planned shortly afterward.Calidi also flagged ongoing efforts to pursue strategic partnerships to accelerate clinical development of RedTail platform.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL2zMQ5h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4139","SG9999014013.SGD","LU2095319765.USD","BK4585","SG9999014021.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4588","CLDI","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624151351","title":"Calidi Biotherapeutics to present AACR data on RedTail TROP-2 T-cell engager candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624151351?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:03","pubTimestamp":1775045020,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics will present new preclinical data at AACR annual meeting in San Diego on April 17-22, 2026 on its RedTail virotherapy approach to in situ T-cell engagers.Presentation will highlight RedTail viruses designed to activate T-cells in tumors while driving local production of a T-cell engager, aiming to improve activity in solid tumors.Calidi is advancing a new RedTail-derived candidate targeting TROP-2, positioning tumor-restricted expression as a way to reduce off-tumor toxicity risk seen with systemic T-cell engagers.Lead RedTail program CLD-401 remains on track for an IND filing by end of 2026, supporting broader platform validation ahead of clinical entry.Company is pursuing strategic partnerships to accelerate clinical development of RedTail-based programs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5Zhpz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","CLDI","IE00BN0W2W23.USD","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808985","title":"Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808985","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808985?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643151,"startTime":"0","endTime":"0","summary":"Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.R&D expense rose 33.33% to USD 2.4 million in Q4, while G&A expense fell 4.55% to USD 2.1 million.Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8W50W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4588","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4139","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622089578","title":"Calidi Biotherapeutics Inc: Q4 Net Loss per Share $0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089578?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643133,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUA4XNBYG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808987","title":"Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808987?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643100,"startTime":"0","endTime":"0","summary":"-- Announced partnership with Australian CRO to accelerate initiation of. -- The Company has received feedback from the FDA through Type D. interactions, and the Company believes its manufacturing and analytical. approaches for CLD-401 are in alignment with FDA guidance; Calidi expects. -- Partnered with Matica Bio around the GMP manufacturing of CLD-401. -- Presented new data on in situ T-cell engagers  at 2026 AACR-IO. SAN DIEGO, March 27, 2026  -- Calidi Biotherapeutics Inc.  , a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.\"We are extremely excited about the continued progress at Calidi,\" said Eric Poma, PhD, CEO of Calidi Biotherapeutics. \"We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts. We have also expa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621106425","title":"BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106425","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106425?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:18","pubTimestamp":1774354706,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory ApprovalMarch 24 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064472","title":"Calidi Biotherapeutics Announces Partnership With Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of Cld-401 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064472?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:16","pubTimestamp":1774354598,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064600","title":"Calidi Biotherapeutics partners with Avance Clinical on CLD-401 trial launch in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064600","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064600?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353885,"startTime":"0","endTime":"0","summary":"Calidi partnered with Avance Clinical to support Australian regulatory approval and accelerate initiation of first-in-human clinical trials for CLD-401 in Australia.The collaboration is intended to facilitate clinical trial initiation in Australia while Calidi pursues an FDA IND filing in 2026.CLD-401 is a genetically modified vaccinia virus designed to replicate only in tumor cells and express an IL-15 superagonist in the tumor microenvironment.The planned phase I trial will evaluate safety and pharmacodynamics in patients with solid tumors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7fnRVd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134673","title":"Calidi Biotherapeutics presents CLD-401 manufacturing process at BioProcessing Summit in Barcelona","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134673?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:03","pubTimestamp":1773316990,"startTime":"0","endTime":"0","summary":"Calidi presented its manufacturing process for CLD-401 at the 9th Annual Bioprocessing Summit in Barcelona. The company said it has received FDA feedback through a Type D meeting request process related to its manufacturing and analytical approaches for CLD-401. Antonio Santidrian and Eric Poma spoke about the manufacturing strategy and regulatory interactions during the event.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2FDp2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","NDAQ","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","CLDI","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618411976","title":"Calidi Biotherapeutics announces proposed underwritten public offering of stock and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2618411976","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618411976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:12","pubTimestamp":1773263543,"startTime":"0","endTime":"0","summary":"Calidi said it plans an underwritten public offering of units consisting of common stock and, for certain investors, pre-funded warrants in lieu of common stock. Each unit will include accompanying common warrants to purchase common stock, and the securities will separate immediately upon issuance. The pre-funded warrants will be priced at the public offering price minus USD 0.001 per share, with an exercise price of USD 0.001 per share. Calidi expects to grant the underwriters a 45-day option to buy up to an additional 15% of the shares and/or common warrants offered. Ladenburg Thalmann is acting as sole book-running manager, and Calidi said it intends to use net proceeds for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL8zKJLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","LTSAP","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618060623","title":"Press Release: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2618060623","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618060623?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:50","pubTimestamp":1773103800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 09, 2026  -- Calidi Biotherapeutics, Inc.  , a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses.In connection with the offering, the Company sold 12,094,631 shares of common stock  Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,631 shares of common stock, and Series L warrants to purchase 12,094,631 shares of common stock, including the full exercise of the underwriter's option to purchase 1,575,000 shares of common stock and accompanying warrants..Ladenburg Thalmann & Co. Inc. acted as sole book-running manager for the offering.This press release does not constitute an offer to sell or the solicitation of an offer to bu","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617263825","title":"BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617263825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617263825?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:34","pubTimestamp":1772804052,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public OfferingMarch 6 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUNCES PRICING OF $5.2 MILLIO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA92TXCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617883716","title":"Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2617883716","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617883716?lang=en_us&edition=fundamental","pubTime":"2026-03-06 15:15","pubTimestamp":1772781300,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics shares plunged after hours following a public offering announcement, trading near their 52-week low.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/06/Stock-Market-Analysis-Shows-Trading-Patt.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/06/Stock-Market-Analysis-Shows-Trading-Patt.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/03/51089549/calidi-biotherapeutics-cldi-stock-plunges-35-after-hours-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/03/51089549/calidi-biotherapeutics-cldi-stock-plunges-35-after-hours-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4150","CLDI","RSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617657213","title":"Calidi announces offering of units, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2617657213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617657213?lang=en_us&edition=fundamental","pubTime":"2026-03-06 07:00","pubTimestamp":1772751646,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics announced that it intends to offer and sell, subject to market and other conditions, units consisting of shares of it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-announces-offering-of-units-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-announces-offering-of-units-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617572540","title":"Calidi Biotherapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617572540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617572540?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:57","pubTimestamp":1772751449,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA4YJHRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}]}}